Abstract: SA-PO1227
Early Clinically Significant Kidney Deterioration After Cancer Diagnosis and One-Year Mortality Across Major Cancer Types
Session Information
- Onconephrology: Epidemiological Trends, Risk Stratification, and Clinical Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1600 Onconephrology
Authors
- Lin, Zi-Han, China Medical University Hospital, Taichung, Taichung City, Taiwan
- Lin, Ming-Hsien, China Medical University Hospital, Taichung, Taichung City, Taiwan
- Chiang, Hsiu-Yin, China Medical University Hospital, Taichung, Taichung City, Taiwan
- Kuo, Chin-Chi, China Medical University Hospital, Taichung, Taichung City, Taiwan
Background
Clinically significant kidney deterioration during early cancer care may identify patients at high risk of poor outcomes, yet pan-cancer evidence remains limited, particularly in Asian populations. We examined kidney deterioration within 3 months after cancer diagnosis and its association with subsequent 1-year mortality across 10 common single primary cancers.
Methods
We conducted a retrospective cohort study of patients with newly diagnosed single primary cancer recorded in the China Medical University Hospital Cancer Registry between 2007 and 2022. The cancer diagnosis date served as the index date. Baseline estimated glomerular filtration rate (eGFR) was calculated from the most recent serum creatinine value within 3 months before diagnosis. Early clinically significant kidney deterioration was defined as the first observed > 40% eGFR decline from baseline within 3 months after diagnosis. One-year mortality was assessed from the index date. Cancer-specific Cox models estimated hazard ratios (HRs), with kidney deterioration modeled as a time-varying exposure and adjusted for age, sex, cancer stage, baseline eGFR, diabetes, hypertension, and initial cancer treatment.
Results
Among 19,323 patients with 10 common cancer types, 60% were male, median age was 63 years, and 40% in stage IV. Overall, 10.9% developed early clinically significant kidney deterioration. The incidence of kidney deterioration was highest in hematologic malignancy (17.3%) and liver cancer (17.2%) and lowest in breast cancer (3.2%). Kidney deterioration was associated with higher 1-year mortality across most cancer types, with the highest adjusted HRs in prostate (aHR 8.4, 95% CI, 4.4-16.1), ovarian (6.6, 2.9-15.2), breast (6.1, 3.2-11.7), and liver cancer (5.3, 4.7-5.9) (Fig 1).
Conclusion
Early clinically significant kidney deterioration was common across major cancer types and was strongly associated with higher 1-year mortality. These findings support early and regular kidney-function surveillance as a proactive strategy for cancer-specific risk stratification and clinical decision support.
Funding
- Government Support – Non-U.S.